Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹83 Cr.
Stock P/E
-43.1
P/B
0.5
Current Price
₹9.5
Book Value
₹ 20.1
Face Value
10
52W High
₹13.8
52W Low
₹ 6.2
Dividend Yield
0%

JHS Svendgaard Labs. Overview

Business

JHS Svendgaard Laboratories Ltd. is an Indian contract manufacturer and marketer of oral care products. The company primarily operates in two key areas: manufacturing toothpaste, toothbrushes, and mouthwashes for other leading Fast Moving Consumer Goods (FMCG) brands (contract manufacturing/OEM) and developing, manufacturing, and marketing its own range of oral care brands. Its flagship own brands include "aquawhite" (focused on kids' oral care and general segments) and "Smyle" (specialty oral care). The company generates revenue by selling its manufactured products to B2B clients (for contract manufacturing) and directly to consumers through retail channels for its own brands.

Revenue Mix

The company's revenue primarily comes from two streams:

Contract Manufacturing (OEM): Manufacturing oral care products for various national and international FMCG players. This segment has historically been a significant contributor to revenue, leveraging the company's manufacturing capabilities and scale.

Own Brands: Sales of products under its proprietary brands like aquawhite and Smyle. The company has been increasingly focusing on expanding its own brand portfolio and market penetration to drive growth and improve margins.

Industry

The Indian oral care industry is large, growing, and highly competitive, dominated by multinational corporations (e.g., Colgate-Palmolive, Hindustan Unilever) and established domestic players (e.g., Dabur, Patanjali). JHS Svendgaard Laboratories Ltd. is positioned as a niche player. In contract manufacturing, it leverages its modern manufacturing facilities and quality standards to serve a range of clients. For its own brands, particularly aquawhite, it targets specific segments such as kids' oral care, attempting to carve out market share against larger rivals through differentiated offerings and competitive pricing.

MOAT

JHS Svendgaard Laboratories Ltd. possesses a moderate competitive advantage primarily derived from:

Manufacturing Expertise & Scale: Established, modern manufacturing facilities with certifications, enabling efficient, high-quality production for both its own brands and contract manufacturing clients. This provides a cost advantage and reliability.

Client Relationships (B2B): Long-standing relationships with several large FMCG companies for contract manufacturing, indicating trust and established supply chain integration.

Brand Building (Emerging): While not yet a dominant moat, its own brands, especially aquawhite, are gaining recognition in specific segments (like kids' toothbrushes), indicating potential for future brand equity development. Switching costs for consumers in oral care are generally low.

Growth Drivers

Rising Oral Care Penetration: Increasing awareness and disposable incomes in India, especially in semi-urban and rural areas, are driving higher demand for oral care products.

Expansion of Own Brands: Increased marketing, wider distribution network, and new product launches under "aquawhite" and "Smyle" can drive market share gains.

Growth in Contract Manufacturing: As large FMCG companies increasingly outsource production, JHS can capitalize on its established reputation and manufacturing capacity.

Premiumization & Specialization: Growing consumer demand for specialized products (e.g., herbal, sensitive, kids-specific, whitening) offers opportunities for new product development.

Export Opportunities: Leveraging manufacturing capabilities to cater to international markets.

Risks

Intense Competition: The oral care market is highly competitive, making it challenging for JHS to gain significant market share against well-entrenched domestic and international players with larger marketing budgets.

Raw Material Price Volatility: Fluctuations in prices of key raw materials (chemicals, packaging) can impact manufacturing costs and profit margins.

Dependency on Contract Manufacturing Clients: A significant portion of revenue may depend on a few large clients; loss of a major client or renegotiation of terms could adversely affect financials.

Brand Building Challenges: High investment required in marketing and distribution to build and sustain brand equity for its own brands in a crowded market.

Regulatory Changes: Changes in food and drug regulations or quality standards for health and hygiene products could necessitate operational adjustments and increased compliance costs.

Management & Ownership

JHS Svendgaard Laboratories Ltd. is a promoter-led company. The Svendgaard family plays a significant role in the management and strategic direction of the company. Promoter shareholding is typically substantial in such Indian companies, indicating a strong vested interest in the company's long-term performance and growth.

Outlook

JHS Svendgaard Laboratories Ltd. is positioned in a growing essential consumer goods sector in India. The company has a strong foundation in contract manufacturing, which provides a steady revenue stream and leverages its core manufacturing expertise. The strategic focus on expanding its own brands, particularly "aquawhite," presents a significant opportunity for margin improvement and long-term value creation if they can successfully penetrate and build brand loyalty in competitive sub-segments. However, the path to sustained market leadership for its own brands will involve overcoming intense competition from well-established giants, requiring significant ongoing investment in marketing, distribution, and product innovation. Its ability to balance the reliable, but potentially lower-margin, contract manufacturing business with the higher-potential, but riskier, own-brand growth strategy will be key to its future success.

JHS Svendgaard Labs. Share Price

Live · BSE / NSE · Inception: 2004
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

JHS Svendgaard Labs. Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 22 24 20 23 25 23 22 23 33 30
Other Income 1 0 1 0 1 1 1 1 1 0
Total Income 23 25 21 23 27 24 23 24 33 30
Total Expenditure 21 23 21 22 31 22 21 22 34 28
Operating Profit 2 2 0 1 -4 3 2 2 -1 2
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 2 2 2 2 2 2 2 2 2 2
Exceptional Income / Expenses 0 0 0 0 -3 0 0 0 0 0
Profit Before Tax 0 0 -2 -2 -9 1 -0 0 -3 0
Provision for Tax 1 1 8 0 -2 -0 0 -1 1 -1
Profit After Tax -1 -1 -10 -2 -7 1 -0 1 -4 1
Adjustments -0 0 -0 0 0 0 -0 0 -0 0
Profit After Adjustments -1 -1 -10 -2 -7 1 -0 1 -4 1
Adjusted Earnings Per Share -0.1 -0.1 -1.2 -0.2 -0.8 0.1 -0 0.1 -0.4 0.1

JHS Svendgaard Labs. Profit & Loss

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 100 105 140 124 139 101 86 85 71 92 102 108
Other Income 1 0 5 7 14 8 9 11 4 3 3 3
Total Income 101 105 145 131 153 108 96 96 75 95 105 110
Total Expenditure 94 93 127 125 137 99 87 94 72 96 99 105
Operating Profit 7 12 19 6 16 9 9 2 3 -1 6 5
Interest 0 1 1 1 2 1 1 1 0 1 1 0
Depreciation 10 6 7 7 9 7 7 6 6 8 7 8
Exceptional Income / Expenses -18 -0 27 0 -11 0 0 -19 0 -3 0 0
Profit Before Tax -22 5 38 -2 -6 1 0 -23 -3 -13 -2 -3
Provision for Tax 0 -17 12 -0 -1 -0 4 -5 1 7 -0 -1
Profit After Tax -22 22 26 -2 -5 1 -4 -18 -4 -20 -2 -2
Adjustments 0 0 0 1 3 -0 0 0 0 0 0 0
Profit After Adjustments -22 22 26 -1 -2 1 -4 -17 -4 -20 -2 -2
Adjusted Earnings Per Share -5.7 5 4.3 -0.1 -0.3 0.2 -0.6 -2.2 -0.5 -2.3 -0.2 -0.2

JHS Svendgaard Labs. Balance Sheet

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 101 134 174 177 178 189 186 174 170 173 175
Minority's Interest 0 -0 -0 4 7 9 9 0 0 0 0
Borrowings 1 1 1 1 1 0 0 0 0 1 6
Other Non-Current Liabilities 1 -16 -4 -4 -3 -4 1 6 -7 -0 -2
Total Current Liabilities 18 20 32 39 48 23 19 37 23 25 33
Total Liabilities 121 138 203 216 230 218 215 217 187 198 211
Fixed Assets 65 65 71 71 66 63 59 65 90 90 89
Other Non-Current Assets 20 31 29 44 34 23 77 67 52 54 58
Total Current Assets 36 43 103 102 130 121 79 85 44 53 63
Total Assets 121 138 203 216 230 218 215 217 187 198 211

JHS Svendgaard Labs. Cash Flow

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 1 3 6 6 1 1 21 5 37 9 7
Cash Flow from Operating Activities -4 -4 14 -11 10 12 -9 23 -9 -5 -3
Cash Flow from Investing Activities 1 -3 -27 -7 -11 -2 -5 10 -21 -20 -12
Cash Flow from Financing Activities 4 10 14 13 0 10 -2 -1 2 23 11
Net Cash Inflow / Outflow 2 3 0 -5 -0 20 -16 32 -28 -2 -3
Closing Cash & Cash Equivalent 3 6 6 1 1 21 5 37 9 7 4

JHS Svendgaard Labs. Ratios

# Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) -5.75 4.98 4.29 -0.11 -0.33 0.19 -0.62 -2.2 -0.52 -2.31 -0.22
CEPS(Rs) -2.96 6.41 5.4 0.89 0.64 1.33 0.43 -1.47 0.29 -1.38 0.64
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 25.2 29.41 28.58 28.97 29.16 27.56 28.6 22.16 21.67 19.88 19.98
Core EBITDA Margin(%) 6.42 11.13 9.64 -0.47 1.19 1.9 -0.98 -10.7 -1.32 -4.36 2.57
EBIT Margin(%) -21.26 5.48 27.46 -0.81 -2.78 2.19 1.74 -26.41 -4.19 -12.98 -1.41
Pre Tax Margin(%) -21.62 4.89 26.94 -1.65 -4.17 0.96 0.12 -27.05 -4.84 -13.6 -2.25
PAT Margin (%) -21.62 20.88 18.27 -1.34 -3.47 1.33 -4.97 -20.65 -5.73 -21.46 -1.89
Cash Profit Margin (%) -11.14 26.93 23.04 4.36 2.79 8.52 3.2 -13.56 3.23 -12.82 5.48
ROA(%) -14.88 16.91 15.25 -0.79 -2.17 0.6 -1.98 -8.11 -2.01 -10.27 -0.94
ROE(%) -20.17 19.53 17.15 -0.95 -2.74 0.76 -2.36 -9.75 -2.36 -11.61 -1.12
ROCE(%) -17.59 4.8 25.01 -0.56 -2.15 1.24 0.82 -12.43 -1.71 -6.8 -0.78
Receivable days 58.65 35.73 72.14 141.83 195.53 280.04 162.56 78.87 80.98 51.46 53.5
Inventory Days 33.41 34.81 25.93 27.26 19.07 31.19 50.23 54.01 66.11 48.67 48.54
Payable days 105.68 122.24 120.92 134.03 145.67 208.84 139.67 166.85 237.71 143.68 152.49
PER(x) 0 7.86 12.49 0 0 107.2 0 0 0 0 0
Price/Book(x) 0.89 1.33 1.88 0.95 0.26 0.72 0.72 0.71 0.76 0.56 0.32
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0.84 1.61 2.3 1.4 0.33 1.07 1.48 1 1.72 0.88 0.5
EV/Core EBITDA(x) 11.78 13.96 17.24 28.67 2.93 11.43 14.93 37.75 36.03 -71.69 8.46
Net Sales Growth(%) 80.91 4.97 33.54 -11.53 12.09 -27.57 -14.4 -1.67 -16.53 29.94 10.54
EBIT Growth(%) 3.26 127.05 580.55 -102.58 -284.7 156.75 -32.21 -1596.63 86.75 -302.38 88.03
PAT Growth(%) 2.42 201.36 18.78 -106.4 -191.19 127.65 -419.53 -308.38 76.84 -386.59 90.26
EPS Growth(%) 37.52 186.69 -13.79 -102.6 -190.7 157.26 -435.46 -253.05 76.52 -345.61 90.47
Debt/Equity(x) 0.03 0.02 0.01 0.04 0 0 0 0 0.02 0.03 0.08
Current Ratio(x) 1.94 2.16 3.24 2.63 2.69 5.23 4.18 2.31 1.87 2.16 1.95
Quick Ratio(x) 1.44 1.64 2.99 2.49 2.61 4.73 3.54 1.96 1.33 1.68 1.48
Interest Cover(x) -58.32 9.31 52.83 -0.98 -1.99 1.78 1.07 -40.98 -6.44 -21.14 -1.66
Total Debt/Mcap(x) 0.03 0.01 0.01 0.04 0.02 0.01 0.01 0 0.03 0.05 0.27

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +11% +6% 0% 0%
Operating Profit CAGR — +44% -8% -2%
PAT CAGR — — 0% —
Share Price CAGR -26% -26% -18% -12%
ROE Average -1% -5% -5% -1%
ROCE Average -1% -3% -4% -1%

JHS Svendgaard Labs. Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 33.85 %
FII 3.14 %
DII (MF + Insurance) 0 %
Public (retail) 63.01 %
# Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter 37.7337.7334.5634.5634.5634.5634.5634.5633.8533.85
FII 2.30.151.691.591.61.591.571.573.63.14
DII 6.216.0500000000
Public 53.7656.0763.7563.8563.8463.8563.8763.8762.5663.01
Others 0000000000
Total 100100100100100100100100100100

JHS Svendgaard Labs. Peer Comparison

Household & Personal Products Edit Columns

JHS Svendgaard Labs. Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

JHS Svendgaard Labs. Pros & Cons

Pros

  • Stock is trading at 0.5 times its book value
  • Company is almost debt free.

Cons

  • Promoter holding is low: 33.85%.
  • Company has a low return on equity of -5% over the last 3 years.
  • Debtor days have increased from 143.68 to 152.49days.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp